fda compounding semaglutide enforcement news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our FDA Update: Current Guidelines for

Zhang W, Waise TMZ, Toshinai K, et al

In the past years, there have been several shortages of incretin medications like Ozempic, Wegovy, and Mounjaro

Labs give us key information about your blood sugar, kidney health, and other health indicators

But the TRIUMPH-4 data already confirm that the Phase 3 results are tracking at or above Phase 2 levels, which is an encouraging sign for TRIUMPH-1

Vomiting patterns help doctors tell normal side effects from gastroparesis

In examining the association between treatment with GLP-1 RAs and the occurrence of psychiatric AEs, we used the ROR to detect psychiatric AE signals in the GLP-1 RA reports